|
1
|
Terashima M, Kitada K, Ochiai A, Ichikawa
W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako
M: Impact of expression of human epidermal growth factor receptors
EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin
Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fujimoto S, Akao T, Itoh B, Koshizuka I,
Koyano K, Kitsukawa Y, Takahashi M, Minami T, Ishigami H, Miyazaki
M, Amamiya K, Ohyama Y, Ono K, Kure M, Kenjiro Itoh and Hikosaka T:
Protracted oral chemotherapy with fluorinated pyrimidines as an
adjuvant to surgical treatment for stomach cancer. Ann Surg.
185:462–466. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Earle CC and Maroun JA: Adjuvant
chemotherapy after curative resection for gastric cancer in
non-Asian patients: revisiting a meta-analysis of randomized
trials. Eur J Cancer. 35:1059–1064. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mari E, Floriani I, Tinazzi A, Buda A,
Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R and Torri
V: Efficacy of adjuvant chemotherapy after curative resection for
gastric cancer: a metaanalysis of published randomized trials. Ann
Oncol. 11:837–843. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K:
Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393.
2011.PubMed/NCBI
|
|
8
|
Calin G and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression
profiles classify human cancers. Nature. 435:834–838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and
Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): a phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Osawa S, Shimada Y, Sekine S, Okumura T,
Nagata T, Fukuoka J and Tsukada K: MicroRNA profiling of gastric
cancer patients from formalin-fixed paraffin-embedded samples.
Oncol Lett. 2:613–619. 2011.PubMed/NCBI
|
|
13
|
Xing Y, Bronstein Y, Ross MI, Askew RL,
Lee JE, Gershenwald JE, Royal R and Cormier JN: Contemporary
diagnostic imaging modalities for the staging and surveillance of
melanoma patients: a meta-analysis. J Natl Cancer Inst.
103:129–142. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakajima G, Hayashi K, Xi Y, Kudo K,
Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs
hsa-let-7g and hsa-miR-181b are associated with chemoresponse to
S-1 in colon cancer. Cancer Genomics Proteomics. 3:317–324.
2006.PubMed/NCBI
|
|
15
|
Haug BH, Henriksen JR, Buechner J, Geerts
D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B
and Einvik C: MYCN-regulated miRNA-92 inhibits secretion of the
tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
Carcinogenesis. 32:1005–1012. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu
P, Song Z, Qian C, Chen Y, Yang S and Wang Y: miR-92b controls
glioma proliferation and invasion through regulating
Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol.
15:578–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ichikawa W, Takahashi T, Suto K, Shirota
Y, Nihei Z, Shimizu M, Sasaki Y and Hirayama R: Simple combinations
of 5-FU pathway genes predict the outcome of metastatic gastric
cancer patients treated by S-1. Int J Cancer. 119:1927–1933. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK,
Noh SH and Chung HC: Predictive values of 5-fluorouracil pathway
genes for S-1 treatment in patients with advanced gastric cancer.
Anticancer Drugs. 22:801–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kai K, Kitajima Y, Hiraki M, Satoh S,
Tanaka M, Nakafusa Y, Tokunaga O and Miyazaki K: Quantitative
double-fluorescence immunohistochemistry (qDFIHC), a novel
technology to assess protein expression: a pilot study analyzing
5-FU sensitive markers thymidylate synthase, dihydropyrimidine
dehydrogenase and orotate phosphoribosyl transferases in gastric
cancer tissue specimens. Cancer Lett. 258:45–54. 2007.
|
|
20
|
Gougelet A, Pissaloux D, Besse A, Perez J,
Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in
osteosarcoma as a predictive tool for ifosfamide response. Int J
Cancer. 129:680–690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faltejskova P, Svoboda M, Srutova K,
Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K,
Kiss I, Vyzula R and Slaby O: Identification and functional
screening of microRNAs highly deregulated in colorectal cancer. J
Cell Mol Med. 16:2655–2666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim YK, Yu J, Han TS, Park SY, Namkoong B,
Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links
between clustered microRNAs: suppression of cell-cycle inhibitors
by microRNA clusters in gastric cancer. Nucleic Acids Res.
37:1672–1681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang CZ, Han L, Zhang AL, Fu YC, Yue X,
Wang GX, Jia ZF, Pu PY, Zhang QY and Kang CS: MicroRNA-221 and
microRNA-222 regulate gastric carcinoma cell proliferation and
radioresistance by targeting PTEN. BMC Cancer. 10:367–376. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui
J and Liu Y: Combination of hsa-miR-375 and hsa-miR-142-5p as a
predictor for recurrence risk in gastric cancer patients following
surgical resection. Ann Oncol. 22:2257–2266. 2011. View Article : Google Scholar : PubMed/NCBI
|
